Drug Combination Details
| General Information of the Combination (ID: C19475) | |||||
|---|---|---|---|---|---|
| Name | Wogonin NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition. | |||||
